Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1515-1525

  Zhang, Manchao ^a,b   Taylor, Christopher E ^c   Piao, Longzhu ^a,b   Datta, Jharna ^a,b   Bruno, Paul A ^c   Bhave, Sanjay ^a,b   Su, Tizhi ^a,b   Lang, James C ^a,b   Xie, Xiujie ^a,b   Teknos, Theodoros N ^a,b   Mapp, Anna K ^c   Pan, Quintin ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BIPHENYL ISOXAZOLIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL RESTRICTED WITH SERINE BOX; ISOXAZOLIDINE DERIVATIVE; LAPATINIB; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HETEROGRAFTS; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 84882246095     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1110     Document Type: Article

References (27)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Rubin Grandis J, MelhemMF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-32.
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
4. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
5. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-62.
6. Choong NW, Cohen EE. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 2006; 57:25-43.
7. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93.
8. Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 2009;15:6484-9.
9. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184-8.
10. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11.
11. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003;303:11-34.
12. Cabral A, Fischer DF, Vermeij WP, Backendorf C. Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation. J Biol Chem 2003;278:17792-9.
13. Oettgen P, Alani RM, Barcinski MA, Brown L, Akbarali Y, Boltax J, et al. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, amember of the ets family.Mol Cell Biol 1997;17:4419-33.
14. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.
15. Tymms MJ, Ng AY, Thomas RS, Schutte BC, Zhou J, Eyre HJ, et al. A novel epithelial-expressed ETS gene, ELF3: Human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 1997;15:2449-62.
16. Schedin PJ, Eckel-Mahan KL, McDaniel SM, Prescott JD, Brodsky KS, Tentler JJ, et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 2004;23:1766-79.
17. Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, et al. Functional proteomics approach to investigate the biological activities ofcDNAs implicated in breast cancer. J ProteomeRes 2006;5:599-610.
18. Walker DM, Poczobutt JM, Gonzales MS, Horita H, Gutierrez-Hartmann A. ESE-1 is required to maintain the transformed phenotype of MCF-7 and ZR-75-1 human breast cancer cells. Open Cancer Journal 2010;3:77-88.
19. Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, et al. ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997;14:1617-22.
20. Neve RM, Ylstra B, Chang CH, Albertson DG, Benz CC. ErbB2 activation of ESX gene expression. Oncogene 2002;21:3934-8.
21. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2001;22:1078-87.
22. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
23. TemamS, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-70.
24. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
25. Asada S, Choi Y, Yamada M, Wang SC, Hung MC, Qin J, et al. External control of Her2 expression and cancer cell growth by targeting a Raslinked coactivator. Proc Natl Acad Sci U S A 2002;99:12747-52.
26. Shimogawa H, Kwon Y, Mao Q, Kawazoe Y, Choi Y, Asada S, et al. A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction. J Am Chem Soc 2004;126:3461-71.
27. Lee LW, Taylor CE, Desaulniers JP, Zhang M, Hojfeldt JW, Pan Q, et al. Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics. Bioorg Med Chem Lett 2009;19:6233-6.